Pomalyst-Cyclophosphamide-Prednisone Combination Effective And Safe In...
Results from a recent Italian Phase 1/2 clinical trial indicate that the combination of Pomalyst, cyclophosphamide, and prednisone is effective and safe in relapsed and refractory multiple...
View ArticleResearchers Publish Final Results Of Pomalyst Trial That Led To Approval In...
Final results from a Phase 3 study show that Pomalyst in combination with low-dose dexamethasone is effective for relapsed and refractory multiple myeloma patients not responding to treatment with...
View ArticleKyprolis Or Pomalyst For Dual-Refractory Myeloma - What Is The Survival Impact?
A new retrospective study provides insight into the benefit the new myeloma drugs Kyprolis and Pomalyst may provide to patients who are resistant to, or cannot tolerate, both Velcade and Revlimid....
View ArticlePomalidomide Approved In Europe For Relapsed And Refractory Multiple Myeloma
The European Commission (EC) has approved pomalidomide for the treatment of certain patients with multiple myeloma. The European brand name for the drug is expected to be “Imnovid,” although final...
View ArticleThe European Hematology Association’s Annual Congress Starts Today: A Look At...
Physicians and researchers have started gathering for the 18th Congress of the European Hematology Association (EHA), which will take place in Stockholm this year. The first education and poster...
View ArticleASCO 2013 And Multiple Myeloma: What Were The Highlights?
This year’s meeting of the American Society of Clinical Oncology (ASCO) was held May 31 through June 4 in Chicago. During the meeting, The Beacon published daily updates that provided overviews of the...
View ArticleASCO 2013 Multiple Myeloma Update – Day Four: Oral Presentations
This year’s annual meeting of the American Society of Clinical Oncology (ASCO) came to an end yesterday in Chicago. Monday was the busiest day with regard to myeloma-related research. The day started...
View ArticleASCO 2012 Multiple Myeloma Update – Day Three: Poster Presentations
This year’s American Society of Clinical Oncology (ASCO) annual meeting, which is being held in Chicago, began on Friday and goes through Tuesday. Sunday started with a poster session in which...
View ArticlePomalidomide Gets Positive Opinion From European Advisory Committee; Approval...
An advisory committee of the European Medicines Agency has issued a positive opinion regarding European approval of pomalidomide for the treatment of certain patients with multiple myeloma....
View ArticleThe Future Of Treatment For Multiple Myeloma
In a recent review article published in the journal Clinical Cancer Research, two myeloma experts from the Dana-Farber Cancer Institute, Dr. Nikhil Munshi and Dr. Kenneth Anderson, review the latest...
View ArticleManhattan Tales: Spring Awakening
One of the advantages of living in the U.S. northeast is the chance to experience the change of the seasons. This year, the arrival of spring coincided with a new medical regimen for me and what...
View ArticleLatest Myeloma Research To Be Presented At The American Society Of Clinical...
The American Society of Clinical Oncology will hold its 49th annual meeting May 31 through June 4 in Chicago. Similar to previous years, more than 25,000 clinical specialists from all over the world...
View ArticleUpdate Presented About Cereblon And Resistance To Pomalyst, Revlimid, And...
During a session at the International Myeloma Workshop (IMW) held in Japan last week, Dr. Keith Stewart from the Mayo Clinic summarized the latest findings from research related to the protein cereblon...
View ArticlePomalyst Plus Low-Dose Dexamethasone Is Active In High-Risk Relapsed Myeloma...
A sub-analysis of recent Phase 2 clinical trial results indicates that Pomalyst in combination with low-dose dexamethasone is effective and safe in multiple myeloma patients with high-risk chromosomal...
View ArticleThe Top Myeloma Research Of 2012
Looking back at all that has happened in the world of multiple myeloma since January of 2012, it is hard not to be impressed by the many important developments that took place. There is the obvious...
View ArticleKyprolis-Revlimid-Dexamethasone Combination Added To NCCN Guidelines As...
The National Comprehensive Cancer Network (NCCN) recently released an updated version of its guidelines for the diagnosis and treatment of multiple myeloma. The most notable change to the guidelines is...
View ArticleFrench Study Provides Further Insights Into Pomalyst’s Efficacy, Safety, And...
The results of a recent French Phase 2 study investigating two Pomalyst (pomalidomide) dosing schedules have been published. The response, survival, and safety data from the study are in line with the...
View ArticlePomalyst – Which Multiple Myeloma Patients Will Physicians Treat With It?
Now that Pomalyst has been approved in the United States as a treatment for multiple myeloma, the drug is available for physicians in the U.S. to prescribe for their patients. The broad availability of...
View ArticlePomalyst – Questions And Answers About The FDA Approval
On Friday, the U.S. Food and Drug Administration (FDA) approved Pomalyst (pomalidomide) for the treatment of multiple myeloma patients who have received at least two prior therapies (see related Beacon...
View ArticlePomalyst (Pomalidomide) Approved By FDA For Relapsed And Refractory Multiple...
The United States Food and Drug Administration (FDA) has approved pomalidomide, which will be marketed under the brand name Pomalyst, for the treatment of relapsed and refractory multiple myeloma....
View Article![BLACKPINK – DEADLINE – EP [iTunes Plus M4A]](http://is1-ssl.mzstatic.com/image/thumb/Video211/v4/de/b3/b1/deb3b1d4-ba28-22e8-2428-ef97617b2a4b/90d54d743002a6d66308f217cd867947_Preview_Image_Intermediate_nonvideo_sdr_426725135_2574858051.png/316x316bb.webp)
